



Sheet 1 Of 1

Modified Form PTO-1449
PATENT & TRADEMARK OFFICE

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)		Alt. Docket No. A-735B	Serial No. 10/197,960 168236
		Applicant Elbaum et al.	
		Filing Date July 17, 2002	Group 1624

U.S. PATENT DOCUMENTS

EXAMINER'S INITIALS	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
A4	0.027,820	May 2000	Altmann et al.			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION YES NO
<i>SM</i>	B23	WO 00/02851	Jan 2000	PCT	—	—	—
<i>SM</i>	B24	DE 19830430	Jan 2000	Germany	—	—	—
<i>SM</i>	B25	EP 1 219 609	3 July 2002	Europe	—	—	—
<i>SM</i>	B26	WO 02/064546	22 Aug 2002	PCT	—	—	—

OTHER DOCUMENTS (Including Publisher, Author, Title, Date, Pertinent Pages, Etc.)

<i>SM</i>	C19	Konshin et al., "Synthesis and antimicrobial activity of arylamides of N-(4-pyridyl)anthranilic acid", Chem. Abstr. 97:109837 (1981).
<i>SM</i>	C20	Breier et al., "The role of vascular endothelial growth factor in blood vessel formation", Trends in Cell Biology 6:454-456 (1996).
<i>SM</i>	C21	Connell et al., "Patent focus on cancer chemotherapeutics. II Angiogenesis agents: April 2000 – September 2000", Exp. Opin. Ther. Patents 11:77-114 (2001).
<i>SM</i>	C22	Chemical Abstract DN 132:93104, also cited as WO 00/02851.
<i>SM</i>	C23	Heinisch et al., "Pyridazines, 89'. on the Synthesis of Novel 1,2-Diazine Containing Tricyclic Systems: Preparation of Dipyridazinodiazepinones", Heterocycles 51(5):1035-1050 (1999).
EXAMINER:	<i>Smolka Bels</i>	
	Date Considered:	<i>8/14/04</i>

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



#7
Sheet 1 Of 1

Modified Form PTO-1449

Atty. Docket No.

A-735B

Serial No.

10823867
10/107,900

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Elbaum et al.

Filing Date

July 17, 2002

Group

1614

U.S. PATENT DOCUMENTS

EXAMINER'S INITIALS	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
A1						
A2						
A3						
A4						

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	PLACE	CLAS.	TRANSLATED	YES	NO
B24				—	—	X	—	
B25				—	—	X	—	
B26				—	—	X	—	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

C8	C8 Auerbach et al. (1994), "Angiogenesis Inhibition: A Review," <i>Pharmac. Ther.</i> 63:265-311. 27
C9	C9 Bagley et al. (2003), "Endothelial Precursor Cells As a Model of Tumor Endothelium: Characterization and Comparison with Mature Endothelial Cells," <i>Cancer Research</i> 63:5866-5873. 28
C10	C10 Carmeliet P. (2000), "Mechanisms of angiogenesis and arteriogenesis," <i>Nature Med.</i> 6:389-395. 29
C11	C11 Hennequin et al. (1999), "Design and Structure--Activity Relationship of a New Class of Potent VEGF Receptor Tyrosine Kinase Inhibitors," <i>J. Med. Chem.</i> 42:5369-5389. 30
C12	C12 Leek R.D. (2001), "The prognostic role of angiogenesis in breast cancer," <i>Anticancer Res.</i> 21:4325-4332. 31
C13	C13 Mehta et al. (2001), "Independent association of angiogenesis index with outcome in prostate cancer," <i>Clin. Cancer Res.</i> 7:81-88. 32
C14	C14 Papamichael D. (2001), "Prognostic role of angiogenesis in colorectal cancer.,," <i>Anticancer Res.</i> 21:4349-4354. 33
C15	C15 Scappaticci FA. (2002), "Mechanisms and future directions for angiogenesis-based cancer therapies," <i>J Clin Onc.</i> 20:3906-3927. 34
C16	C16 Stewart et al. (2003), "The angiogenic receptor KDR is widely distributed in human tissues and tumours and relocates intracellularly on phosphorylation. An immunohistochemical study," <i>Histopathology</i> 43:33-39. 35
C17	C17 Wang et al. (2002), "Expression and endocytosis of VEGF and its receptors in human colonic vascular endothelial cells," <i>Am. J. Physiol. Gastrointest Liver Physiol</i> 282:G1088-G1096. 36
C18	C18 Wang et al. (2000), "Homeostatic Modulation of Cell Surface KDR and Flt1 Expression and Expression of the Vascular Endothelial Cell Growth Factor (VEGF) Receptor mRNAs by VEGF," <i>J. Biol. Chem.</i> 275(21):15905-15911. 37

EXAMINER:

Date Considered:

11/03/04 8/12/04

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Modified Form PTO-1449

Atty. Docket No.
A-735BSerial
No. 168258
10197,160

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant
Elbaum et al.Filing Date
July 17, 2002Group
1624

#5

U.S. PATENT DOCUMENTS

EXAMINER'S INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
	A1	3,226,394	12/28/65	Schipper, et al. 1			
	A2	5,532,358	7/2/96	Kelly 2			
	A3	6,140,351	10/31/00	Arnaiz, et al. 3			

FOREIGN PATENT DOCUMENTS

EXAMINER'S INITIALS		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION YES NO
	B1	EP 0 947 500 A1	10/6/99	Europe 4	—	—	— —
	B2	FR 2 168 227	8/31/73	France 5	—	—	— X
	B3	JP 2000 256358	9/19/00	Japan 6	—	—	— X
	B4	WO 96/41795	12/27/96	PCT 7	—	—	— —
	B5	WO 98/24771	6/11/98	PCT 8	—	—	— —
	B6	WO 98/45268	10/15/98	PCT 9	—	—	— —
	B7	WO 99/32477	7/1/99	PCT 10	—	—	— —
	B8	WO 99/62885	12/9/99	PCT 11	—	—	— —
	B9	WO 00/02851	1/20/00	PCT 12	—	—	— —
	B10	WO 00/27819	5/3/00	PCT 13	—	—	— X
	B11	WO 00/27820	5/18/00	PCT 14	—	—	— —
	B12	WO 00/39111	7/6/00	PCT 15	—	—	— —
	B13	WO 00/39117	7/6/00	PCT 16	—	—	— —
	B14	WO 01/29009 A1	4/26/01	PCT 17	—	—	— —
	B15	WO 01/30745 A1	5/3/01	PCT 18	—	—	— —
	B16	WO 01/55114 A1	8/2/01	PCT 19	—	—	— —
	B17	WO 01/55115 A1	8/2/01	PCT 20	—	—	— —
	B18	WO 01/81311 A1	11/1/01	PCT 21	—	—	— X
	B19	WO 01/85671 A2	11/15/01	PCT 22	—	—	— X
	B20	WO 01/85691 A1	11/15/01	PCT 23	—	—	— X
	B21	WO 01/85715 A2	11/15/01	PCT 24	—	—	— X

REC'D
TECH CENTER 1600
DEC 24 2002
USPTO

J. Schipper, et al.
 8/14/01

Modified Form PTO-1449		Atty. Docket No. A-735B	Serial No. 10/187,160 10/8758
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)		Applicant Elbaum et al.	
		Filing Date July 17, 2002	Group 1624

U.S. PATENT DOCUMENTS

EXAMINER'S INITIALS	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
---------------------	-----------------	------	------	-------	-----------	----------------------------

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

<i>SB</i>	C1	Singh, et al., "Substituted Imidazolines and Their CNS Activity" Ind.J.Het.Chem. 2: 129-132 (1992) 25
<i>SB</i>	C2	Seto, et al., "Molecular Self-Assembly through Hydrogen Bonding: Supramolecular Aggregates Based on the Cyanuric Acid-Melamine Lattice" J.Am.Chem.Soc. 115: 905-916 (1993) 26

RECEIVED
DEC 24 2002
TECH CENTER 1600/2900

EXAMINER: <i>Subha Btcl</i>	Date Considered: <i>11/10/03 - 8/14/04</i>
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	



Sheet 1 Of 1

Modified Form PTO-1449

Atty. Docket No.

A-735B

Serial No.

10/197,960
10 823809

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Elbaum et al.

Filing Date

July 17, 2002

Group

1624

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION YES	NO
B22	WO 02/055501	18 July 2002	PCT	—	—	—	—
B23	WO 03/024935	27 Mar 2003	PCT	—	—	—	—

EXAMINER:

Subhankar B. Chakrabarty

Date Considered:

DEC 19 2003

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

TRADEMARK 10/197,960/2000

THIS PAGE BLANK (USPTO)

BEST AVAILABLE COPY